Plasma cholesterol in Alzheimer’s disease and frontotemporal dementia

Abstract Background The relationship between the apolipoprotein E (APOE)-ε4 allele, triglyceride (TG) level, and cholesterol level and an increased risk of developing Alzheimer’s disease (AD) has been well established, but their relationship with behavioral-variant frontotemporal dementia (bvFTD) is not well-known. Methodology The levels of TGs, total cholesterol (TC), low-density lipoprotein (LDL), and high-density lipoprotein were measured in bvFTD and AD patients and in normal controls (NCs). DNA was extracted, and APOE was genotyped. Results The APOE-ε4 allele frequency was higher in the AD group than in the NC group, but no difference was found between the AD and the bvFTD groups. The bvFTD group had higher LDL than the AD group, and significant differences were also found for the cholesterol level in the dementia groups compared with the NC group. Elevated LDL level was positively correlated with appetite and eating score in the bvFTD group. Compared with the AD patients and NCs without the APOE-ε4 allele, those with the APOE-ε4 allele had higher TC, but its correlation with the bvFTD group was absent. Conclusions The bvFTD and the AD groups had higher cholesterol levels. The APOE-ε4 allele and eating behavior might modify lipid metabolism in dementia. TG and cholesterol analyses may offer a new opportunity for targeted treatments.

[1]  P. Svenningsson,et al.  On the fluxes of side-chain oxidized oxysterols across blood-brain and blood-CSF barriers and origin of these steroids in CSF (Review) , 2019, The Journal of Steroid Biochemistry and Molecular Biology.

[2]  L. Goldstein,et al.  Cholesterol Metabolism Is a Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived Alzheimer’s Disease Neurons , 2019, Cell stem cell.

[3]  J. Hodges,et al.  Lipid Metabolism and Survival Across the Frontotemporal Dementia-Amyotrophic Lateral Sclerosis Spectrum: Relationships to Eating Behavior and Cognition. , 2017, Journal of Alzheimer's disease : JAD.

[4]  P. Rothwell,et al.  Total small vessel disease score and risk of recurrent stroke , 2017, Neurology.

[5]  Guowei Huang,et al.  Factors Associated with Frontotemporal Dementia in China: A Cross-Sectional Study. , 2016, Archives of medical research.

[6]  S. Humphries,et al.  Effect of SORT1, APOB and APOE polymorphisms on LDL-C and coronary heart disease in Pakistani subjects and their comparison with Northwick Park Heart Study II , 2016, Lipids in Health and Disease.

[7]  J. Hodges,et al.  Assessment of Eating Behavior Disturbance and Associated Neural Networks in Frontotemporal Dementia. , 2016, JAMA neurology.

[8]  G. Vranken,et al.  Analytical Performance Verification of the Beckman Coulter AU5800 Clinical Chemistry Analyser Against Recognized Quality Specifications Reveals Relevance of Method Harmonization. , 2016, Clinical laboratory.

[9]  J. Hodges,et al.  Eating behavior in frontotemporal dementia , 2015, Neurology.

[10]  Murray Grossman,et al.  Frontotemporal lobar degeneration: defining phenotypic diversity through personalized medicine , 2015, Acta Neuropathologica.

[11]  J. Hodges,et al.  Quantifying the eating abnormalities in frontotemporal dementia. , 2014, JAMA neurology.

[12]  J. Hodges,et al.  Systemic metabolism in frontotemporal dementia , 2014, Neurology.

[13]  T. Ohm,et al.  Tau Pathology Induces Intraneuronal Cholesterol Accumulation , 2014, Journal of neuropathology and experimental neurology.

[14]  C. DeCarli,et al.  Associations between serum cholesterol levels and cerebral amyloidosis. , 2014, JAMA neurology.

[15]  M. Pierer,et al.  Cholesterol in mild cognitive impairment and Alzheimer’s disease in a birth cohort over 14 years , 2014, European Archives of Psychiatry and Clinical Neuroscience.

[16]  Nick C Fox,et al.  Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration , 2013, The Lancet Neurology.

[17]  G. Lippi,et al.  Evaluation of the analytical performances of the novel Beckman Coulter AU5800. , 2012, Clinical biochemistry.

[18]  Nick C Fox,et al.  Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. , 2011, Brain : a journal of neurology.

[19]  G. D. Paolo,et al.  Linking lipids to Alzheimer's disease: cholesterol and beyond , 2011, Nature Reviews Cancer.

[20]  V. Haroutunian,et al.  Cholesterol and LDL relate to neuritic plaques and to APOE4 presence but not to neurofibrillary tangles. , 2011, Current Alzheimer research.

[21]  G. D. Paolo,et al.  Linking lipids to Alzheimer's disease: cholesterol and beyond , 2011, Nature Reviews Neuroscience.

[22]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[23]  Steve Meaney,et al.  Oxysterols and neurodegenerative diseases. , 2009, Molecular aspects of medicine.

[24]  J. Hodges,et al.  Sensitivity of current criteria for the diagnosis of behavioral variant frontotemporal dementia , 2009, Neurology.

[25]  S. Akterin,et al.  P3-414: Activity-regulated cytoskeleton-associated protein in rodent brain is down-regulated by high fat diet in vivo and by 27-hydroxycholesterol in vitro , 2008, Alzheimer's & Dementia.

[26]  A. Nordberg,et al.  Regulation of α- and β-secretase activity by oxysterols: Cerebrosterol stimulates processing of APP via the α-secretase pathway , 2007 .

[27]  A. Nordberg,et al.  Regulation of alpha- and beta-secretase activity by oxysterols: cerebrosterol stimulates processing of APP via the alpha-secretase pathway. , 2007, Biochemical and biophysical research communications.

[28]  I. Björkhem,et al.  Oxysterols and Alzheimer's disease , 2006, Acta neurologica Scandinavica. Supplementum.

[29]  P. Schofield,et al.  Differences in regional brain atrophy in genetic forms of Alzheimer's disease , 2006, Neurobiology of Aging.

[30]  Christine M. Williams,et al.  Saturated fat-induced changes in Sf 60–400 particle composition reduces uptake of LDL by HepG2 cells Published, JLR Papers in Press, November 8, 2005. , 2006, Journal of Lipid Research.

[31]  M. M. Mielke,et al.  High total cholesterol levels in late life associated with a reduced risk of dementia , 2005, Neurology.

[32]  K Yaffe,et al.  Midlife cardiovascular risk factors and risk of dementia in late life , 2005, Neurology.

[33]  M. Eriksson,et al.  Patients with atherosclerosis may have increased circulating levels of 27‐hydroxycholesterol and cholestenoic acid , 2005, Scandinavian journal of clinical and laboratory investigation.

[34]  M. Mattson,et al.  Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[35]  K. Zou,et al.  Amyloid β‐protein (Aβ)1–40 protects neurons from damage induced by Aβ1–42 in culture and in rat brain , 2003 .

[36]  G. Kolovou,et al.  Apolipoprotein E Polymorphism and Atherosclerosis , 2003, Angiology.

[37]  W. Kamphorst,et al.  Apolipoprotein E ε4 in an autopsy series of various dementing disorders , 2003 .

[38]  K. Zou,et al.  Amyloid beta-protein (Abeta)1-40 protects neurons from damage induced by Abeta1-42 in culture and in rat brain. , 2003, Journal of neurochemistry.

[39]  W. Kamphorst,et al.  Apolipoprotein E epsilon 4 in an autopsy series of various dementing disorders. , 2003, Journal of Alzheimer's disease : JAD.

[40]  J. Hillert,et al.  Changes in human plasma levels of the brain specific oxysterol 24S-hydroxycholesterol during progression of multiple sclerosis , 2002, Neuroscience Letters.

[41]  B. Dubois,et al.  Apolipoprotein E gene in frontotemporal dementia: an association study and meta-analysis , 2002, European Journal of Human Genetics.

[42]  Peter Schönknecht,et al.  Cerebrospinal fluid 24S-hydroxycholesterol is increased in patients with Alzheimer's disease compared to healthy controls , 2002, Neuroscience Letters.

[43]  Berrit C Stroehla,et al.  Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. , 2002, American journal of epidemiology.

[44]  B Miller,et al.  Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. , 2001, Archives of neurology.

[45]  D. Bennett,et al.  Association of incident Alzheimer disease and blood pressure measured from 13 years before to 2 years after diagnosis in a large community study. , 2001, Archives of neurology.

[46]  M. Viitanen,et al.  Increased risk for frontotemporal dementia through interaction between tau polymorphisms and apolipoprotein E epsilon4. , 2001, Neuroreport.

[47]  Rong Wang,et al.  Hypercholesterolemia Accelerates the Alzheimer's Amyloid Pathology in a Transgenic Mouse Model , 2000, Neurobiology of Disease.

[48]  R. Havlik,et al.  Midlife blood pressure and dementia: the Honolulu–Asia aging study☆ , 2000, Neurobiology of Aging.

[49]  D. Geschwind,et al.  The apolipoprotein E ε4 allele is not a significant risk factor for frontotemporal dementia , 1998 .

[50]  P. Scheltens,et al.  Familial aggregation in frontotemporal dementia , 1998, Neurology.

[51]  D. Geschwind,et al.  The apolipoprotein E epsilon4 allele is not a significant risk factor for frontotemporal dementia. , 1998, Annals of neurology.

[52]  P. de Knijff,et al.  Apolipoprotein E gene and sporadic frontal lobe dementia , 1997, Neurology.

[53]  K. Blennow,et al.  The apolipoprotein E ϵ4 allele frequency is normal in fronto-temporal dementia, but correlates with age at onset of disease , 1997, Neuroscience Letters.

[54]  Stephen W. Scheff,et al.  Induction of Alzheimer-like β-Amyloid Immunoreactivity in the Brains of Rabbits with Dietary Cholesterol , 1994, Experimental Neurology.

[55]  PhilipR. Wenham,et al.  Apolipoprotein E genotyping by one-stage PCR , 1991, The Lancet.

[56]  C. Sing,et al.  Apolipoprotein E polymorphism and atherosclerosis. , 1988, Arteriosclerosis.

[57]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.